Peptides: separating evidence from marketing
Most peptide marketing runs ahead of the evidence, and the gap is widest exactly where the promises are boldest. Some peptides are well-studied, approved medicines with decades of trial data behind them. Others are compounds whose entire public case rests on cell-culture work, rodent studies and testimonials. The two get sold in the same language, and telling them apart is a skill worth having.
This is not an argument for or against any particular compound. It is a method for reading the claim in front of you — and a note on what your bloodwork can honestly tell you if you go ahead.
Dear Life does not prescribe, supply or recommend peptides. Anything in this category is a conversation for you and a treating doctor.
Key takeaways
A peptide is a short chain of amino acids. The word describes a chemical structure, not a level of safety or evidence.
Approved peptide medicines and unapproved compounds are marketed almost identically. The regulatory status is the fastest way to separate them.
Mechanism is not evidence. A plausible pathway explains how something might work, not whether it does.
"Research use only" is a supply category, not a safety assessment.
Bloodwork can monitor some downstream effects and safety markers. It cannot verify what was in the vial.
What is a peptide, exactly?
A peptide is a chain of amino acids shorter than a full protein — typically a few to a few dozen residues. Insulin is a peptide. So are the GLP-1 medicines, parathyroid hormone analogues and a long list of ordinary hormones your body makes constantly.
That breadth is the source of the confusion. Because the category includes some of the most rigorously tested drugs in modern medicine, marketing for compounds with almost no human data can borrow the credibility of the category as a whole. "Peptides are naturally occurring" is true and tells you nothing: so are digitalis and botulinum toxin.
How do you grade the evidence behind a claim?
Almost every peptide claim can be placed on this ladder within a couple of minutes of searching. Where it sits should determine how much weight you give it.
Evidence level | What it shows | What it does not show |
|---|---|---|
Cell culture (in vitro) | The compound does something to cells in a dish | Whether it survives digestion, reaches tissue, or does anything in a person |
Animal studies | An effect in a living organism, usually at high doses | Translation to humans. Most promising animal findings fail in people. |
Small open-label human studies | Everyone knew who got what; outcomes were observed | How much of the result was expectation, selection or regression to the mean |
Randomised controlled trials | Effect against a comparator with the obvious biases controlled | Rare harms and long-term outcomes, unless the trial was large and long |
Systematic reviews and meta-analyses | What the whole body of trials shows together | Little, when done well — this is the strongest routine evidence available |
The practical question is simple: where on that ladder does the evidence for this specific compound, for this specific outcome, in this specific population, actually sit? A compound with strong RCT evidence for one indication is not thereby supported for another.
Which marketing patterns should make you slow down?
Mechanism presented as proof. A diagram of a signalling pathway is an explanation of how an effect could occur. It is not evidence that it does.
Study citations that do not match the claim. The linked paper is often in rats, at a dose that does not scale, measuring a different endpoint entirely. Open the abstract and check the species, the sample size and the outcome measured.
Endpoint substitution. A marker moved, therefore health improved. Sometimes true, often not — surrogate markers and real outcomes come apart routinely.
Testimonials doing the heavy lifting. Anecdotes are unreliable precisely because people who feel better are the ones who post.
"Research use only" framing. That label describes how something is legally supplied. It is not a statement that the compound has been assessed as safe for people.
Purity claims without independent testing. A certificate supplied by the seller is not third-party verification, and unregulated supply chains have a documented history of mislabelled and contaminated product.
Urgency and scarcity. Legitimate clinical decisions do not expire at midnight.
If you can't understand it, we haven't finished writing it. The same standard is worth applying to anyone selling you something.
What is the regulatory position in Australia?
Broadly: a small number of peptide medicines are registered on the Australian Register of Therapeutic Goods and available on prescription for defined indications. A great many more of the compounds discussed in longevity and performance circles are not registered, and the settings around compounded and imported peptides have been tightening rather than loosening.
Two practical points follow. Importing unapproved therapeutic goods for personal use is governed by specific rules that most sellers do not explain accurately, and products supplied outside the registered system carry no assurance of identity, purity or dose. If you are considering anything in this category, the status of that specific compound is worth confirming directly with a treating doctor rather than with the person selling it.
What can bloodwork actually monitor?
Some things, honestly and usefully:
Baseline before anything changes. Without a pre-intervention panel there is nothing to compare against, and every subsequent result becomes an argument.
General safety markers. Liver enzymes, kidney function, full blood count and inflammatory markers will show organ strain, whatever the cause.
Metabolic and glucose handling. Fasting glucose, insulin and HbA1c respond to anything acting on that axis.
Specific downstream markers where the mechanism genuinely predicts one — IGF-1 for growth-hormone-axis compounds being the obvious case.
Hormonal axes that a compound is claimed to influence, measured under consistent conditions.
And some things it cannot do at all. Bloodwork cannot tell you what was in the vial, whether the dose was what the label said, or whether an improvement in how you feel came from the compound rather than from the sleep, training and diet changes that usually accompany starting something new. It also will not detect most rare harms, which is what trials are for.
A baseline panel read as a whole is the genuinely useful part here, and it is worth understanding what bloodwork can and cannot tell you before relying on it to referee a decision.
What should you ask before starting anything?
What is the best human evidence for this compound, for this outcome — and what did the control group do?
Is it registered for therapeutic use here, and if not, on what basis is it being supplied?
Who is monitoring me, and which markers would tell us early if this is going badly?
What are the known interactions with my medications and my existing results?
What would make us stop?
What would the same money and attention buy if spent on sleep, training, iron status or thyroid function instead?
That last question is not rhetorical. A surprising share of the symptoms people take peptides for turn out to be depleted iron stores, a thyroid pattern nobody read properly, or an ordinary hormonal transition — all of which are measurable, and all of which have better-established answers.
Frequently asked questions
Are peptides safe?
The question cannot be answered for the category. Some peptides are approved medicines with well-characterised safety profiles; others have essentially no human safety data, and products bought outside the regulated system carry additional risks of contamination and mislabelling. Safety is a question about a specific compound from a specific source.
What does "research use only" mean?
It is a supply designation indicating the product is not being sold for human use. It says nothing about whether the compound is effective or safe in people, and it is frequently used as a workaround rather than a warning.
Can a blood test show whether a peptide is working?
Sometimes, if the compound has a specific downstream marker and you have a genuine baseline. More often, bloodwork shows whether anything is going wrong rather than whether the intended benefit is occurring.
Does Dear Life recommend or supply peptides?
No. We do not prescribe, supply or recommend any therapeutic product. We explain what results show; decisions about treatment sit with you and your doctor. That boundary is deliberate, and you can read more about how we work.
What should I test before starting something new?
A comprehensive baseline covering metabolic markers, liver and kidney function, full blood count, inflammation, thyroid, iron and the hormonal axis relevant to the compound in question — drawn before anything changes, so later panels have something to be compared with.
Starting from a real baseline
If you are weighing up an intervention of any kind, the most useful thing you can do first is understand where you actually stand. A DearLife 360 reads your full panel as a pattern, bands each finding, and sets out the questions worth taking to a doctor. If you need the panel arranged as well, that can be organised.